0001558370-24-006594.txt : 20240503 0001558370-24-006594.hdr.sgml : 20240503 20240503080013 ACCESSION NUMBER: 0001558370-24-006594 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240501 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24910825 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20240501x8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 1, 2024

HARMONY BIOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-39450	82-2279923
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

630 W. Germantown Pike, Suite 215

Plymouth Meeting, PA 19462

(Address of principal executive offices) (Zip Code)

(484) 539-9800

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, $0.00001 par value per share	HRMY	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

The Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Kumar Budur, M.D., M.S., the Company’s Chief Medical Officer, to the title of Executive Vice President and Chief Medical & Scientific Officer (the “Appointment”), effective on May 1, 2024 (the “Effective Date”). Biographical and other information required by Item 5.02(c)(2) and (3) of Form 8-K regarding Dr. Budur has been previously disclosed by the Company in its Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 11, 2024, which information is incorporated herein by reference.

In connection with the Appointment, the Compensation Committee of the Board approved an increase to Dr. Budur’s annual base salary (from $500,000 to $575,000) effective as of the Effective Date. Dr. Budur’s annual target bonus opportunity remains the same at 50% of his annual base salary. In addition, in connection with the Appointment, the Company will grant Dr. Budur a restricted stock unit (“RSU”) award covering 75,000 shares of the Company’s common stock, and an option award to purchase 75,000 shares of the Company’s common stock, each of which vest over four years, subject to Dr. Budur’s continued employment.

In connection with the Appointment, Dr. Budur’s employment arrangement was amended and is qualified in its entirety by reference to the full text of such original offer letter and subsequent letters, which are filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit
No.		Description

10.1		Employment Letter between Harmony Biosciences, LLC, and Kumar Budur, as amended

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	HARMONY BIOSCIENCES HOLDINGS, INC.

Date: May 3, 2024	By:	/s/ Jeffrey M. Dayno
		Jeffrey M. Dayno
		President, Chief Executive Officer and Director

EX-10.1 2 hrmy-20240501xex10d1.htm EX-10.1

‌Exbibit 10.1

Revised

March 1, 2022

Dr. Kumar Budur

701 South Wells Street

#2103

Chicago, IL 60607

Dear Kumar:

On behalf of Harmony Biosciences, LLC (“Harmony Biosciences” or the “Company”), I am pleased to extend an offer of employment with the Company as Senior Vice President and Head of Clinical Development. Except for business travel on behalf of the Company, you will be a remote employee and work from your home office. This position will report to the Chief Medical Officer or their designee.

Your start date will be mutually determined but we anticipate it to be on or around March 21, 2022. We are excited about the possibility of you joining our team and hope you will accept our offer to join us in executing our growth plans for the Company. You will have an important role to play at Harmony Biosciences where we share a singular purpose to address true unmet needs by developing new medicines for people who live with rare diseases.

The terms of your employment offer are outlined below:

●

Bi-monthly base pay of $16,458.34 which, when annualized, is equivalent to a base salary of $395,000 per year.

●

Participation (pro-rated for the calendar year in which your actual start date occurs) in the Harmony Biosciences, LLC Performance Bonus Plan at up to 40% of your base salary based on Company and individual achievement. Your bonus will be based on your performance meeting established individual goals and objectives to support the growth strategy of the Company, as well as the Company’s overall performance.

●

Equity in the Company’s parent company, Harmony Biosciences Holdings, Inc. (“Parent”) in the amount of 75,000 stock options for Parent common stock with an exercise price equal to the fair market value of a share of our common stock on the grant date.

●

In consideration of the money left behind at your current employer for 2021 performance shares and LTI, you will receive a sign-on bonus of $250,000 (subject to applicable tax and other withholding), paid to you in two installments. The first will be $150,000 and paid within three months of your start date. The second will be $100,000 and paid by March 21, 2023. Both payments require that you are an active employee in good standing at the time of payment. In the event you voluntarily leave the Company within 12 months after receiving the first payment or 12 months after receiving the second payment, you must pay back the full amount of that payment but on an after-tax basis to Harmony.

●

As a full-time Company employee, you will accrue paid vacation and sick leave. Vacation will accrue at a rate of 1.25 days per month, or 15 days per year.

●

As a remote employee, you will receive a phone/cable allowance of up to $150 a month.

Harmony Biosciences, LLC 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462

●

As a full-time employee of the Company, except as expressly provided for above, you are eligible to participate in the provided Harmony Biosciences, LLC Employee Benefit Plans.

●

This offer is contingent upon successful completion of Harmony’s pre-employment process, including background verification and drug testing. By signing and returning a copy of this offer letter to me, you expressly consent to such background verification (including dates of employment and previous employer salary) and other pre-employment processes. In addition, you will be required to sign a non-competition and confidentiality agreement.

●

All prospective hires will be required to demonstrate that they have been fully vaccinated* for COVID-19 or intend to be fully vaccinated for COVID-19 prior to their hire date. Upon acceptance of this offer, and within 7 days of your start date, please email proof of vaccination (a photo or scan of your vaccination card) to HRConfidential@harmonybiosciences.com. If you believe that you qualify for a medical or sincerely held religious belief exemption to this vaccination requirement, please contact me as soon as possible to initiate the accommodation request process. [*In general, people are considered “fully vaccinated” two (2) weeks after their second dose in a 2-dose series (such as Pfizer or Moderna vaccines) or two (2) weeks after a single-dose vaccine (such as Johnson & Johnson’s Janssen vaccine).]

You will devote all of your time and attention to the Company (including, but not limited to, its business, operations and success) and shall not compete with the Company in any way during your employment.

This offer of employment, if not previously accepted by you, will expire ten (10) days after the date first set forth above. This offer of employment does not represent an employment contract. Just as you retain the right to resign, with or without notice or cause, Harmony Biosciences has the same right with respect to termination of your employment. You will be an employee-at-will, and your employment is for no definite term, regardless of any other oral or written statement by any Harmony Biosciences officer or representative, with the exception of an express written employment contract signed by the CEO of the Company. Notwithstanding anything in this offer of employment to the contrary, if your actual start date does not occur on or prior to April 21, 2022 this offer of employment will be null and void in its entirety (even if previously accepted by you).

If you understand and accept these terms, please sign and return one copy of this offer letter to me. We would be pleased to have you join Harmony Biosciences and be a part of continuing to build a great company. If you have any questions regarding this offer, please contact me at (484) 539-9814.

Sincerely,

/s/Audrey H. Murhpy, SPHR

Audrey H. Murphy, SPHR

Vice President, Human Resources

Agreed to and Accepted by:

/s/ Kumar Budur

Kumar Budur

Harmony Biosciences, LLC 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462

January 24, 2024

MEMORANDUM

To: Kumar Budur

From: Jeff Dayno

Subject: 2023 Bonus, Merit Increase, and Promotion Increase Awards

Dear Kumar:

I greatly appreciate the hard work and focus you have demonstrated during this past year. Your ongoing dedication to the continuing development and growth of Harmony will help us continue to fulfill our mission of helping people living with rare neurological disorders.

Based on your superior performance and Harmony’s business needs, you are being promoted to the position of Executive Vice President, Chief Medical Officer. Congratulations on your promotion, which will benefit not only your career, but Harmony’s continued growth as well.

In light of your accomplishments this year, I am pleased to present you with the following bonus, merit increase and promotion increase:

Bonus:$207,017.66

Merit Increase:4.5%

Promotion Increase:6.7%

2023 Salary:$450,038.40

2024 Salary:$500,442.70

The target bonus for your new position is 50%.

Your bonus will be paid on January 31, 2024, and the merit and promotion increases will be effective January 1, 2024. You will see your new salary in your January 31^st pay, as well as a retroactive payment reflecting January 1^st – 15^th.

Please accept this financial reward, which you have earned, with my regards and best wishes for a successful start of the new year as we continue as a high-performing team throughout 2024.

Harmony Biosciences, LLC 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462

May 01, 2024

MEMORANDUM

To: Dr. Kumar Budur

From: Dr. Jeffrey Dayno

Subject: Appointment Confirmation

Dear Kumar:

As approved by our Board of Directors, I am pleased to confirm your appointment to the position of Executive Vice President and Chief Medical & Scientific Officer. Congratulations on your appointment, which will benefit not only your career, but Harmony’s continued growth as well.

In light of your accomplishment, I am pleased to present you with the following promotion increase:

Promotion Increase:15%

Current Salary:$500,000

New Salary:$575,000

The target bonus for your new position is 50%.

Your promotion increase will take effect as of May 1, 2024.

I am also pleased to confirm that you will receive an additional grant of equity in the Company’s parent company, Harmony Biosciences Holdings, Inc. (“Parent”) in the amount of 75,000 Restricted Stock Units (RSUs) and 75,000 stock options for Parent common stock with an exercise price equal to the fair market value of a share of our common stock on the grant date, May 1, 2024. RSU and stock option agreements with full details for this grant will be provided to you.

Please accept this financial reward which you have earned, with my regards and best wishes for continued success and personal fulfillment in your new role.

Harmony Biosciences, LLC 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA 19462

GRAPHIC 3 hrmy-20240501x8k001.jpg GRAPHIC begin 644 hrmy-20240501x8k001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" " .D# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#\U_\ A;WC MO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9 M_P#XNC_A;WCO_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO M_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^ M+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^+HHH /\ A;WC MO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9 M_P#XNC_A;WCO_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO M_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^ M+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^+HHH /\ A;WC MO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9 M_P#XNC_A;WCO_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO M_H=?$7_@UG_^+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^ J+HHH /\ A;WCO_H=?$7_ (-9_P#XNC_A;WCO_H=?$7_@UG_^+HHH __9 end GRAPHIC 4 hrmy-20240501xex10d1001.jpg GRAPHIC begin 644 hrmy-20240501xex10d1001.jpg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end

GRAPHIC 5 hrmy-20240501xex10d1002.jpg GRAPHIC begin 644 hrmy-20240501xex10d1002.jpg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hrmy-20240501.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 hrmy-20240501_lab.xml EX-101.LAB Document and Entity Information [Abstract] Amendment Flag Entity Central Index Key Document Type Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Adress Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity Emerging Growth Company EX-101.PRE 8 hrmy-20240501_pre.xml EX-101.PRE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	May 01, 2024
Document and Entity Information [Abstract]
Amendment Flag	false
Entity Central Index Key	0001802665
Document Type	8-K
Document Period End Date	May 01, 2024
Entity File Number	001-39450
Entity Registrant Name	HARMONY BIOSCIENCES HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2279923
Entity Address, Address Line One	630 W. Germantown Pike
Entity Address, Adress Line Two	Suite 215
Entity Address, City or Town	Plymouth Meeting
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19462
City Area Code	484
Local Phone Number	539-9800
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.00001 par value per share
Trading Symbol	HRMY
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports hrmy-20240501.xsd hrmy-20240501_lab.xml hrmy-20240501_pre.xml hrmy-20240501x8k.htm hrmy-20240501x8k001.jpg http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hrmy-20240501x8k.htm": { "nsprefix": "hrmy", "nsuri": "http://www.harmonybiosciences.com/20240501", "dts": { "schema": { "local": [ "hrmy-20240501.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hrmy-20240501_lab.xml" ] }, "presentationLink": { "local": [ "hrmy-20240501_pre.xml" ] }, "inline": { "local": [ "hrmy-20240501x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_5_1_2024_To_5_1_2024_4I49eWIvAker9sP0zoPklw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240501x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_1_2024_To_5_1_2024_4I49eWIvAker9sP0zoPklw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240501x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001558370-24-006594-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-006594-xbrl.zip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end XML 20 hrmy-20240501x8k_htm.xml IDEA: XBRL DOCUMENT 0001802665 2024-05-01 2024-05-01 0001802665 false 8-K 2024-05-01 HARMONY BIOSCIENCES HOLDINGS, INC. DE 001-39450 82-2279923 630 W. Germantown Pike Suite 215 Plymouth Meeting PA 19462 484 539-9800 false false false false Common Stock, $0.00001 par value per share HRMY NASDAQ false